Biotech Industry Examiner

Menu
Menu
subscribe now
Search
The FDA wants to “pre-check” factories before the medicine exists

The FDA wants to “pre-check” factories before the medicine exists

On February 1, 2026, the U.S. Food and Drug Administration

Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up

Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up

A few years ago, Emergent BioSolutions’ Bayview plant in Baltimore

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing

The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing

Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T

Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T

Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case

Abu Dhabi Wants to Own Longevity Biotech—and Juvenescence Is the Test Case

Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?

Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?

MOST POPULAR

News

The FDA wants to “pre-check” factories before the medicine exists
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation
Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug?
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top